Management of cognition and fatigue

Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study

Context:

Fatigue is one of the most common and disabling symptoms of multiple sclerosis (MS); however, there is no medication that has been approved specifically to treat MS-related fatigue.

Objective:

We aimed to evaluate the effect of vitamin D analogue, Alfacalcidol, on MS-related fatigue.

Design, settings, participants:

This was a randomized, double-blind, parallel group, placebo-controlled trial in patients with clinically definite MS by McDonald criteria conducted in a single university-affiliated medical center in Israel. Randomly selected patients from the Sheba MS Registry computerized database ( N=600) were assessed using the self-report Fatigue Severity Scale (FSS). Patients with clinically meaningful fatigue ( N=259) were further assessed for trial eligibility, and MS patients with significant fatigue ( N=158; 61%, 118 females, mean age 41.1 ± 9.2 years and mean disease duration of 6.2 ± 5.5 years) were included in the study and randomized to receive treatment or placebo.

Intervention:

Alfacalcidol (1 mcg/d, N=80) or placebo ( N=78) was administered for six consecutive months.

Main outcome measure:

The primary endpoint of the study was the change between Alfacalcidol and placebo-treated patients in the Fatigue Impact Scale (FIS) score; the cut-off point for improvement was defined as 30% decrease. All analyses followed the intention-to-treat principle and were performed for all participants based on the group they were randomly allocated regardless of whether or not they dropped out.

Results:

Alfacalcidol decreased the mean relative FIS score as compared with placebo (–41.6% vs. –27.4%, p=0.007, respectively). This advantage was further emphasized when the modified FIS (MFIS) relative change was calculated. Quality of Life (QoL) improved in Alfacalcidol-treated patients as compared with placebo in the RAYS psychological ( p=0.033) and social ( p=0.043) sub-scales. The Alfacalcidol-treated group had reduced number of relapses ( p=0.006) and higher proportion of relapse-free patients ( p=0.007). Reduction of relapses by Alfacalcidol became significant at 4 months of treatment, was sustained at 6 months and decayed 2 months after drug discontinuation. Alfacalcidol treatment was safe and no serious adverse events were recorded.

Conclusion:

Alfacalcidol is a safe and effective treatment strategy to decrease fatigue and improve QoL in patients with MS.